Lead Product(s) : HTL0018318
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Allergan Aesthetics
Deal Size : $3,290.0 million
Deal Type : Termination
Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
Details : AbbVie has notified that it will be returning to Sosei Heptares all assets in development under the program including HTL0018318, all intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $125.0 million
May 01, 2021
Lead Product(s) : HTL0018318
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Allergan Aesthetics
Deal Size : $3,290.0 million
Deal Type : Termination
Lead Product(s) : HTL0018318
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Sosei Group Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2018
Lead Product(s) : HTL0018318
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Sosei Group Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HTL0018318
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Allergan
Deal Size : Inapplicable
Deal Type : Inapplicable
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2018
Lead Product(s) : HTL0018318
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Allergan
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HTL0018318
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2017
Lead Product(s) : HTL0018318
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HTL0018318
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2016
Lead Product(s) : HTL0018318
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable